Jump to main content
Volume number3 (3)
2つ以上の標準的な治...

2つ以上の標準的な治療が無効又は治療後に再発した、大細胞型B細胞リンパ腫又は濾胞性リンパ腫に対するエプコリタマブの費用対効果評価

Icons representing 記事
The cover of this title could differ from library to library. Link to Help Page

2つ以上の標準的な治療が無効又は治療後に再発した、大細胞型B細胞リンパ腫又は濾胞性リンパ腫に対するエプコリタマブの費用対効果評価

Persistent ID (NDL)
info:ndljp/pid/14712665
Material type
記事
Author
柏宗伸ほか
Publisher
国立保健医療科学院
Publication date
2025
Material Format
Digital
Journal name
Academic technology assessment group (ATAG) reports 3(3)
Publication Page
-
View All

Notes on use

Note (General):

一部被覆あり

Bibliographic Record

You can check the details of this material, its authority (keywords that refer to materials on the same subject, author's name, etc.), etc.

Digital

Material Type
記事
Author/Editor
柏宗伸
此村恵子
森脇健介
小嶋智美
前田知美
白岩健
下妻晃二郎
福田敬
Publication, Distribution, etc.
Publication Date
2025
Publication Date (W3CDTF)
2025
Alternative Title
Cost-effectiveness evaluation of epcoritamab for relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments
Periodical title
Academic technology assessment group (ATAG) reports
No. or year of volume/issue
3(3)
Volume
3(3)